Newamsterdam Pharma Company N.V. (NAMS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2026 | 03-2026 | 12-2025 | 09-2025 | 06-2025 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 425,508 | 458,943 | 491,323 | 539,715 | 563,864 |
| Marketable Securities | 209,703 | 178,498 | 146,239 | 164,539 | 175,298 |
| TOTAL | $659,207 | $658,044 | $675,700 | $732,328 | $769,850 |
| Non-Current Assets | |||||
| PPE Net | 411 | 379 | 383 | 323 | 312 |
| Investments And Advances | 44,409 | 71,239 | 92,609 | 53,091 | 44,172 |
| Intangibles | 343 | 375 | 407 | 439 | 470 |
| Other Non-Current Assets | 82 | 2,606 | 185 | 246 | 308 |
| TOTAL | $45,245 | $74,599 | $93,584 | $54,099 | $45,262 |
| Total Assets | $704,452 | $732,643 | $769,284 | $786,427 | $815,112 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 5,422 | 8,090 | 8,970 | 3,632 | 5,895 |
| Accrued Expenses | 10,277 | 5,092 | 15,422 | 10,098 | 9,460 |
| Other current liabilities | 54,452 | 50,229 | 57,272 | 44,361 | 20,932 |
| TOTAL | $72,974 | $67,421 | $85,787 | $58,272 | $36,512 |
| Non-Current Liabilities | |||||
| Deferred Revenues | 2,797 | 3,987 | 3,987 | N/A | N/A |
| Other Non-Current Liabilities | 56 | 0 | 66 | 85 | 103 |
| TOTAL | $56 | $N/A | $66 | $85 | $103 |
| Total Liabilities | $73,030 | $67,421 | $85,853 | $58,357 | $36,615 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | N/A | 116,904 | 114,975 | 113,391 | 112,629 |
| Common Shares | 14,735 | 14,594 | 14,278 | 14,107 | 14,014 |
| Retained earnings | -874,966 | -810,831 | -762,390 | -687,467 | -615,462 |
| Other shareholders' equity | 3,861 | 4,221 | 4,793 | 4,640 | 4,327 |
| TOTAL | $631,422 | $665,222 | $683,431 | $728,070 | $778,497 |
| Total Liabilities And Equity | $704,452 | $732,643 | $769,284 | $786,427 | $815,112 |